Repligen (NASDAQ:RGEN) Cut to Hold at Wall Street Zen

Repligen (NASDAQ:RGEN) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group set a $160.00 price objective on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. Evercore ISI boosted their price objective on shares of Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Wells Fargo & Company decreased their price objective on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Wednesday, July 30th. Finally, Barclays boosted their price objective on shares of Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.85.

Repligen Stock Performance

Shares of RGEN stock opened at $150.17 on Tuesday. Repligen has a one year low of $102.96 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The company has a 50 day moving average price of $135.99 and a 200 day moving average price of $129.03. The firm has a market capitalization of $8.45 billion, a price-to-earnings ratio of 7,512.26, a price-to-earnings-growth ratio of 3.32 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The firm had revenue of $188.80 million during the quarter, compared to analyst estimates of $181.23 million. During the same quarter in the prior year, the business posted $0.43 earnings per share. Repligen’s revenue for the quarter was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Sell-side analysts anticipate that Repligen will post 1.72 EPS for the current year.

Insider Buying and Selling

In related news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the purchase, the director directly owned 1,800 shares of the company’s stock, valued at $201,834. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.20% of the stock is owned by company insiders.

Institutional Trading of Repligen

Institutional investors and hedge funds have recently modified their holdings of the business. Harvest Fund Management Co. Ltd acquired a new stake in shares of Repligen during the first quarter worth $132,000. XTX Topco Ltd raised its holdings in shares of Repligen by 34.2% during the first quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company’s stock worth $1,646,000 after purchasing an additional 3,295 shares during the period. Congress Asset Management Co. raised its holdings in shares of Repligen by 18.0% during the second quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock worth $18,962,000 after purchasing an additional 23,231 shares during the period. Dynamic Technology Lab Private Ltd raised its holdings in shares of Repligen by 233.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company’s stock worth $1,172,000 after purchasing an additional 6,448 shares during the period. Finally, TD Asset Management Inc increased its holdings in shares of Repligen by 10.9% in the 1st quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company’s stock worth $6,511,000 after acquiring an additional 5,014 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.